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Abstract: Erlotinib hydrochloride (Tarceva) is a member of a class of small molecule inhibi-
tors that targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), 
with anti-tumor activity in preclinical models. Erlotinib represents a new-generation of agents 
known as “targeted therapies” designed to act upon cancer cells by interfering with aberrant 
specific activated pathways needed for tumor growth, angiogenesis and cell survival. Since its 
approval in November 2004 for the treatment of locally advanced or metastatic non-small cell 
lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen and with 
a view to improving patients’ outcomes and prevent symptoms, the scientific community has 
evaluated the potential role of erlotinib in other scenarios such as in maintenance therapy and, 
in first-line   setting for a selected population based on biological markers of response such as 
mutations of the EGFR. The convenient once-a-day pill administration and the good toxicity 
profile of   erlotinib make it a reasonable candidate for testing in this context. This report provides 
a review of the role of erlotinib therapy in advanced NSCLC. It summarizes current data and 
perspectives of erlotinib in upfront treatment and maintenance for advanced NSCLC as well as 
looking at candidate biomarkers of response to these new targeted-agents.
Keywords: erlotinib, tyrosine kinase inhibitors, first line, maintenance, non-small-cell lung 
cancer
Introduction
Erlotinib is a class of the newly named “targeted therapies”, designed to inhibit the 
epidermal growth factor receptor (EGFR) (Figure 1). The small molecule was designed 
to bind to the ATP pocket of the intracellular tyrosine kinase domain of the EGFR, 
inhibiting the phosphorylation and thereby blocking the initiation of the intracellular 
cascade of transduction signals.1,2 The EGFR is part of a well-known member of the TK 
receptors family, with key functions in regulating proliferation, apoptosis,   angiogenesis 
and metastasis, necessary to sustain cancer cells’ growth and   progression in various 
solid tumors such as non-small-cell lung cancer (NSCLC).3,4 Erlotinib is indicated for 
the treatment of all subgroups of advanced NSCLC after   failure of at least one prior 
chemotherapy regimen and for the treatment of patients with   metastatic pancreatic 
cancer in combination with gemcitabine.5,6 This oral tyrosine kinase inhibitor (TKI) 
is also recommended in third-line treatment of advanced NSCLC after   second-line 
chemotherapy failure.7 More recently erlotinib has gained another indication and 
has been approved as maintenance treatment for patients with locally advanced or 
metastatic NSCLC whose disease has not progressed after 4 cycles of platinum-based 
first-line chemotherapy. Erlotinib, administered once a day orally, is very convenient Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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for patients and associated toxicities are mild, the most 
common being skin rash and diarrhea (9% and 6% grade 
3/4 respectively).6
Lung cancer is the leading cause of cancer-related mor-
tality;8 the overwhelming majority of lung cancers, almost 
80%, belong to the “non-small” major histotype subgroup and 
about 50% of the patients are presented with extensive disease 
at the time of diagnosis. During the last 2 decades, we have 
moved from the situation in which there was believed to be 
no effective treatment for this distinctive aggressive disease 
to one in which new targeted agents have been developed 
along with innovative biomarkers used to identify individu-
als that are more likely to benefit from these therapies. This 
shift started in the 1980s with the first randomized trials that 
demonstrated the benefit of cisplatin-based chemotherapy in 
terms of survival, quality of life (QoL) and relieved symptoms 
in advanced NSCLC patients.9 Subsequently, the introduction 
of third-generation cytotoxic drugs to the platinum agents 
(known as doublets), including paclitaxel, docetaxel, gem-
citabine and vinorelbine, gave rise to higher response rates 
(RRs) and longer overall survival (OS).10 This led to platinum 
doublets becoming standard in first-line advanced NSCLC 
treatment. With these new generation agents in advanced 
NSCLC, we can predict RRs of 20% to 30%, with a median 
survival of 8 to 12 months and a 1-year survival rate of 30% to 
40%10. Since then, other trials have demonstrated the efficacy 
of new cytotoxic agents such as pemetrexed, a thymidylate 
synthase inhibitor,11 and new targeted agents used in first-line 
setting combined with chemotherapy, such as bevacizumab 
an anti-vascular endothelial growth factor (VEGF) inhibitor 
or cetuximab, an EGFR inhibitor.12–14 Hence, the choice of 
optimal treatment for advanced NSCLC is no longer limited 
to the different platinum-based doublets.15 Likewise, in the 
second-line   setting, which represents a small part of the 
population (around 30%–50% according to different phase 
III trials) due to clinical deterioration,11,12,14,16 prognostic 
improvement has been also achieved: first with the approval 
of single agent, docetaxel, which proved to be superior to 
placebo in OS and symptoms control17 and more recently with 
the approval of pemetrexed and erlotinib,18,19 drugs with a 
more favorable toxicity profile than docetaxel. However, some 
questions remains to be answered, such as what is be best 
duration of the second-line treatment and which is the optimal 
time to introduce them. Recently, fresh information has been 
gathered on the treatment of advanced NSCLC. For the first 
time in NSCLC, there is evidence of distinct sensitivity to 
chemotherapy depending on the histological subtype.11,19,20 
It has been observed that in patients with squamous histol-
ogy the efficacy of pemetrexed-platinum combinations is 
limited compared to gemcitabine combinations, whereas 
in non-squamous histology groups there is a benefit in OS 
with the addition of pemetrexed, leading the introduction of 
pemetrexed in first-line setting of advanced NSCLC with 
the indication restricted to the non-squamous subtypes.11,15 
Second, the identification of molecular markers to guide the 
selection of specifically targeted types of therapy, ensuring 
better efficacy without unnecessary side effects. The most 
remarkable advance in this field has been the recognition of 
aberrant activation of the EGFR as a marker of response to 
TKI such as erlotinib.21–23
This review focuses specifically on erlotinib, a small 
molecule inhibitor of the EGFR tyrosine kinase, as part of 
the treatment for advanced NSCLC in two new scenarios: 
in the first-line setting, and as maintenance therapy contin-
ued beyond a first-line induction chemotherapy regimen. 
An overview of the pharmacogenomic properties of the drug 
in NSCLC, as well as candidate biomarkers for identifying 
subgroups of patients that benefit from erlotinib treatment, 
is also reviewed.
Pharmacogenomic properties  
of erlotinib in NSCLC
The EGFR family of TKs, referred to as the HER/ErbB 
family, consists of 4 members-EGFR (HER1/ErbB1), 
HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4)-that 
regulate many developmental, metabolic and physiological 
  processes. The intracellular TK activity of EGFR is increased 
as a   consequence of the binding of various ligands, which 
include EGF, transforming growth factor-α, amphiregulin, 
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Figure  1  Erlotinib  hydrochloride  molecule:  N-(3-ethynylphenyl)-6,7-bis(2-
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epiregulin and others, leading to the homodimerization of 
2 EGFRs or the heterodimerization of EGFR with other 
family and   non-family members including HER2, HER3 and 
insulin growth factor receptor 1 (IGFR-1R).24,25
The activation of TK receptor leads to the autophospho-
rylation of the intracellular domain of the EGFR, and the 
  phosphotyrosine residues that are formed act as a docking site 
for various adapter molecules, resulting in the activation of 
the Ras/mitogen-activated protein kinase (MAPK) pathway, 
the PI3K/Akt pathway and signal   transducers and activators 
of transcription signaling pathways.26 In tumor cells, the TK 
activity of EGFR may be deregulated by various oncogenic 
mechanisms, including EGFR gene mutation, increased gene 
copy number and EGFR protein overexpression.27 Improper 
activation of EGFR TK results in increased malignant cell 
survival, proliferation, invasion and metastasis.28
Mutations in the EGFR have long been known to cause 
a constitutive, growth factor-independent activation of the 
EGFR downstream pathways and are frequently found in 
malignant diseases including brain tumors29 and NSCLC.21–23 
The presence of these mutations in NSCLC correlates with 
responsiveness to reversible and irreversible TKIs. In a nota-
ble retrospective study, Shigematsu et al reported the genomic 
analysis of more than 2000 NSCLCs; EGFR   mutations were 
found to be more common in   adenocarcinoma (30%) than in 
lung cancers of other histologies (2%), and more frequent in 
lung cancer from never- (45%) than   ever-smokers (7%).30
A number of distinct alterations have been identified 
including point mutations within the nucleotide-binding loop 
in exon 18, small deletions in exon 19 or insertions in exon 20, 
as well as point mutations in the activation loop in exon 21. 
Structurally, these mutations cluster around the active site 
cleft of the TK domain. The two most frequent mutations 
are the exon 19 deletion that removes residues 746–750 of the 
expressed protein (48.2%) and the exon 21 point substitution 
that replaces leucine 858 with arginine – L858R (42.7%).31,32 
The L858R substitution is the single most common   mutation, 
and it lies in the activation loop (A-loop) of the kinase. Other 
point mutations are observed in glycine 719, although less 
frequently; Gly719 is found in the adjacent phosphate-binding 
P-loop of the kinase, and is substituted with serine, cysteine 
or alanine. The L858R and G719S point mutations, as well as 
the exon 19 deletions and exon 20 insertions, can transform 
both, fibroblasts and lung epithelial cells, in the absence of 
exogenous epidermal growth factor.33–36
Interestingly, the clinical correlation between the   presence 
of specific mutations and therapeutic response to TKIs is mir-
rored in cell lines and EGFR-transfected cells. Cells bearing 
the mutant EGFR are in general more   sensitive to TKIs than 
cells expressing the wild-type kinase. In   particular, the L858R 
mutant is 10- to 100-fold more sensitive to erlotinib and 
gefitinib than the wild-type kinase22,35,37,38 and significantly 
more sensitive than the G719S mutant.39 At the same time, 
there are exceptions to this rule, for example the fact that the 
exon 20 mutants are highly resistant to both gefitinib and 
erlotinib further underscores the dependence of inhibitor 
responses on specific mutations.40
Erlotinib structure is based on the 4-anilino-quinazoline 
kinase pharmacophore. Crystallography studies suggests that 
selective inhibitors of the EGFR bind to the ATP-binding 
pocket, with the aniline head group fitting into the selectivity 
pocket of EGFR.41,42 When examined in an in vitro enzyme 
analysis, erlotinib has shown comparable binding affinities 
(Ki) values against wild-type (3.86 nmol/L) and L858R 
mutant EGFR (4.76 nmol/L) and no significant differences 
in activity were found across an enzyme panel of more than 
200 isolated targets (predominantly kinases).43 In the same 
way, erlotinib showed a high correlation in growth inhibitory 
activity across a panel of 34 NSCLC cell lines (Pearson’s 
r = 0.975), including 3 cell lines harboring activating EGFR 
mutations. Similar activity was observed in the assessment 
of pharmacodynamic biomarkers of erlotinib activity that 
showed a high dose response relationship because of the inhi-
bition of pEGFR, cell proliferation measured by inhibition of 
BrdU uptake, and apoptosis (annexin V labeling).44
Erlotinib in first-line treatment  
of advanced NSCLC
Currently, screening for common EGFR mutations in patients 
with NSCLC can be performed in the clinical setting to   predict 
which patients will respond to EGFR TKIs.45,46 A   seminal 
work recently published by the Spanish Lung   Cancer Group 
(SLCG) demonstrates the feasibility of   large-scale screening 
of EGFR mutations and analyzed the association between this 
condition and clinical outcomes to erlotinib therapy.46 From 
the analysis of more than 2000 NSCLC cases,   mutations in 
the EGFR were found in 350 patients (16.6%). The mutations 
were detected more frequently in women, never-smokers, and 
in patients with adenocarcinoma (30%, 37.7% and 17.3%, 
respectively). Erlotinib was administered to 217 patients, 
of whom 113 received the TKI as first-line therapy and 104 
as second- or third-line therapy. EGFR exon 19 deletions 
were detected in 135 cases, and the L858R point mutation 
in 82 tumors. The RR with erlotinib was 70.6%, 12.2% pre-
sented complete responses and a better outcome was associ-
ated with the exon 19 deletion than with the L858R mutation Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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(odds ratio 3.08; P = 0.001).46 This registry also reveals 
a median progression-free survival (PFS) of 14 months, 
a period that was similar between patients receiving first or 
second-line therapy. There were no significant differences 
in PFS according to performance status (PS), age, first vs 
second or third-line therapy, or smoking history. Median OS 
was 27 months and the multivariate analysis found that PS 
1, male sex, the presence of the L858R mutation, brain 
metastases, and bronchioloalveolar adenocarcinoma were 
associated with poor prognosis.46
Until now, there have been no published randomized tri-
als of EGFR TKIs vs chemotherapy as first-line therapy for 
NSCLC patients from Western countries; however, 2 integrative 
  studies of phase II trials support the findings of the SLCG 
and promote the role of erlotinib as first-line therapy for 
patients with NSCLC carrying EGFR mutations. Jackman 
et al pooled the data of 5 first-line phase II trials designed to 
prove the role of erlotinib or gefitinib monotherapy in patients 
in whom EGFR mutations were assessed.47 However, patients 
were customized in only one study to receive gefitinib 
based on the presence of this genetic condition.48 A total of 
317 chemotherapy-naïve patients were treated with erlotinib 
or gefitinib, and tumor specimens from 223 of these patients 
were tested for EGFR mutations. Tumors from 84 selected 
patients were found to harbor a sensitizing EGFR mutation. 
Eighty-one percent of EGFR-mutant patients were women, 
89% had adenocarcinoma, and 58% had no smoking history. 
Of the 84 patients harboring a sensitizing EGFR mutation 
treated with erlotinib or gefitinib, 67% achieved an objective 
response, with a median PFS of 11.8 months and a median 
OS of 23.9 months.47 In contrast, for 83 patients with wild-
type EGFR and wild-type Kras, the RR was 5%, the PFS 
was 3.1 months, and the OS was 11.8 months. Finally, in 
41 patients with wild-type EGFR and mutated Kras, RR was 
0%, PFS was 3.3 months, and OS was 13 months.   Outcomes 
of the 84 patients with EGFR mutations were also compared 
according to the EGFR directed therapy; 56 and 28 patients 
received erlotinib and gefitinib, respectively. There were no 
significant differences in RR (erlotinib 70% and gefitinib 
60%; P = 0.47), median PFS (erlotinib 13 months and 
  gefitinib 11.4 months; P = 0.49), or OS (erlotinib 28.7 months 
and gefitinib 20.8 months; P = 0.10).47
Following the same perspective Paz-Ares et al added 
the information from twelve trials of erlotinib (n = 365), 
39 of gefitinib (n = 1069) and 9 trials that assessed the role 
of   chemotherapy (375 patients) as first-line therapy for 
patients with EGFR mutations.49 In the weighted pooled 
analysis, the overall median PFS was 13.2 months with 
erlotinib, 9.8 months with gefitinib, and 5.9 months with 
  chemotherapy. Using a 2-sided permutation analysis, 
erlotinib and gefitinib produced a longer median PFS vs 
chemotherapy, both individually (P = 0.000 and P = 0.002, 
respectively) and as a combined group (EGFR TKI vs 
  chemotherapy, P = 0.000).49
More information is available from patients with EGFR 
mutations treated with TKIs in Asia; recently, Mok et al 
reported the final data of the IPASS study (Iressa Pan-Asia 
Study) that found a significant interaction between treatment 
and EGFR mutation with respect to PFS (P , 0.001).50 
This outcome was significantly longer among patients 
receiving gefitinib than among those receiving carboplatin/
paclitaxel in the mutation-positive subgroup (hazard ratio 
[HR] 0.48; 95% confidence interval [CI] 0.36 to 0.64; 
P , 0.001) and   significantly shorter among patients receiv-
ing gefitinib than among those receiving chemotherapy 
in the mutation-negative group (HR 2.85; 95% CI 2.05 to 
3.98; P , 0.001).   Similarly, results in the subgroup with 
unknown EGFR-mutation status were similar to those for 
the overall population.50 These data were confirmed by a 
homologous multicenter phase II study which included 30 
chemotherapy-naïve patients with poor PS who had EGFR 
mutations and received gefitinib alone. The overall RR was 
66% (90% CI 51% to 80%), and the disease control rate was 
90%. PS improvement rate was 79% (P , 0.00005) and the 
median PFS, median OS, and 1-year survival rate were 6.5 
months, 17.8 months, and 63%, respectively.51
Morita et al evaluated and integrated 7 published phase II 
trials of gefitinib as a single first-line therapy for NSCLC 
patients with EGFR mutations treated in Asia and performed 
a pooled analysis based on individual data.52 A total of 148 
patients were included; 69% were women, 71% were never-
smokers, and 97% have adenocarcinoma. The RR was sig-
nificantly higher (79.3 vs 24.6%; P , 0.001), and PFS was 
longer (10.7 vs 6 months; P , 0.001) for patients receiving 
the TKI than in those receiving chemotherapy, whereas there 
was no significant difference in OS between the two groups 
of patients (27.7 vs 25.7 months).52 Interestingly, the Cox 
regression analysis revealed that PFS after gefitinib treatment 
was significantly longer in the chemotherapy-naïve patients 
than those who had received previous chemotherapy. This 
result highlights the fact that first-line chemotherapy could 
have a detrimental effect on the later use of EGFR TKIs in 
NSCLC patients harboring EGFR mutations.53 Currently 
there are 2 ongoing phase III trials, which aim to give more 
insights into the role of the erlotinib in the first-line setting 
of patients harboring EGFR mutations (Figures 2 and 3): the Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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EURTAC trial (NCT00446225),54 from European countries, 
and the OPTIMAL trial (NCT00874419) in Asia.55 Both tri-
als randomized chemotherapy-naïve NSCLC EGFR-mutant 
patients to receive erlotinib vs chemotherapy, PFS being the 
primary end-point in both studies.
Role of erlotinib as maintenance 
therapy in advanced NSCLC
Erlotinib was the first new class of drugs against a specific 
molecular target directed to a TK that demonstrate single-
agent activity in advanced NSCLC patients. Erlotinib was first 
evaluated in a randomized, double-blind, placebo-controlled 
trial with 731 patients with advanced NSCLC who had 
previously received one or more prior chemotherapy regimens 
(BR.21).18 Patients were randomized to receive either oral 
erlotinib 150 mg/daily or a placebo. The primary end-point 
was OS that favor the group of patients treated with erlotinib 
(6.7 months vs 4.7 months; P , 0.001) with an adjusted HR 
of 0.70 (95% CI 0.58 to 0.85). The benefit in survival was 
consistent among the different patient subgroups based on 
sex, histology and smoking habits. However, patients never-
smokers got more benefit than did smokers (HR 0.42 and 
0.87, respectively).56 RR and PFS were also significantly 
higher (P , 0.001) with erlotinib than with the placebo group 
Primary end-point: PFS
Secondary end-points: ORR, 1-year survival, OS, safety, QoL, localization of PD
Phase III study initiated by the Spanish Lung Cancer Group (GECP)
recruitment ongoing in Spain, Italy and France
Platinum-based doublet 
chemotherapy
R
Chemo-naÏve advanced NSCLC •
EGFR mutation-positive •
(exon 19 or L858R)
• ECOG PS 0–2
• n~150
Figure 2 Design of the phase III trial of erlotinib in first-line advanced NSCLC with EGFR mutations in Europe: the EURTACC trial.54
Abbreviations: eCOG, Eastern Oncology Cooperative Group; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; ORR, objective response 
rate; PD, progressive disease; QoL, quality of life.
Secondary end-points: ORR, OS, QoL and safety
Phase III study initiated by Tongji University, Shanghai, China
recruitment ongoing in China
R
Primary end-point: PFS
Chemo-naÏve advanced NSCLC
EGFR mutation-positive
•
•
•
•
(exon 19 or 21)
ECOG PS 0–2
n~150
Figure 3 Design of the phase III trial of erlotinib in first line advanced NSCLC with EGFR mutations in Asian population: the OPTIMAL trial.55
Abbreviations: eCOG, Eastern Oncology Cooperative Group; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; PD, progressive disease; 
PFS, progression-free survival; ORR, overall response rate; OS, overall survival; QoL, quality of life.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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(8.9% vs 1% and 2.2 vs 1.8 months respectively) and although 
the side effects were higher in the erlotinib arm, most adverse 
events were mild or moderate.18 On the basis of data from the 
BR21 trial,18 erlotinib was approved by the US Food and Drug 
Administration (FDA) in November 2004 for the treatment of 
all subtypes of advanced NSCLC after failure of at least one 
prior chemotherapy regimen.6 At the moment, together with 
docetaxel and pemetrexed, erlotinib remains the standard of 
treatment in second-line advanced NSCLC. Nonetheless, one 
question remains unanswered; it is not yet known which of 
the three drugs approved in second-line treatment should be 
selected, unless the criterion of toxicity profile is applied. A 
randomized phase III biomarker validation study of second-
line therapy of erlotinib versus pemetrexed in patients with 
advanced NSCLC (NCCTG-N0723) aims to shed some light 
on this issue.57
Currently, second-line treatment in advanced NSCLC 
is indicated if there is a relapse or disease progression after 
the first-line platinum-based combination and most patients 
who are treated with first-line chemotherapy will experience 
disease progression within 3 or 4 months.10 The term “main-
tenance” therapy is usually used when one of the drugs used 
in the upfront combination treatment is maintained beyond 
the initial 4 to 6 cycles of chemotherapy, generally as first-
line treatment, until disease progression or unacceptable 
toxicity (Figure 4). The continuous administration of therapy 
after the recommended 4 to 6 treatment cycles is used with 
patients for whom the treatment has been demonstrated to be 
effective, ie, patients with a stabilization or tumor response 
with the up-front chemotherapy, which accounts around 
75% of the treated population. There is some semantic 
controversy   surrounding the use of the word “maintenance” 
and the switch to another non-cross resistant drug early after 
first-line therapy without progression is also referred to as 
“early second-line” or “consolidation” therapy. In advanced 
NSCLC, there has been a renewed interest in assessing both 
the duration of the up-front treatment as well as when to 
start the second-line treatment. It is worth mentioning that in 
advanced NSCLC, there is no standard approach to follow-up 
the tumor growth and consequently there is concern about 
our ability to detect disease progression before it impairs 
patient’s condition. When lung cancer patients experience 
tumor growth their physical condition promptly deteriorates 
due to the distinctive aggressive behavior of this disease, 
restricting the options for further treatments.11,12,14,16 There-
fore the rationale of the maintenance therapy approach is to 
improve the outcomes, by maintaining the initial responses to 
the platinum-doublet therapy, as well as the QoL, by delaying 
cancer-related symptoms.
Several old trials investigated the role of longer platinum-
based combinations with old cytotoxic agents and failed to 
demonstrate a survival advantage.58–63 The idea of “the more 
Increase PFS
Diagnostic CR/PR/SD PD PD
Maintenance treatment
Diagnostic CR/PR/SD
First-line treatment 
Platinum doublet
(4 to 6 cycles) ‘Wait and see’
PD
Second-line
PD
Second-line
Figure 4 Current strategies to treat advanced NSCLC patients.
Abbreviations: NSCLC, non-small-cell lung cancer; PD, progressive disease; CR, complete response; PR, partial response; SD, stable disease.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
149
erlotinib
chemotherapy the better” was finally laid to rest with a recent 
meta-analysis which corroborated the absence of a survival 
advantage in advanced NSCLC with the continuation of the 
same platinum-based chemotherapy beyond the standard 4 to 
6 cycles in first-line setting.64 The meta-analysis performed 
with PFS as end-point (n = 1907) showed the advantage in 
PFS with extending chemotherapy duration, more evident 
when a third-generation agent was used,64 but it is worth not-
ing that QoL analysis was not assessed in all the trials and in 
the few in which it was, a trend to worsening QoL, in terms of 
chemotherapy-related side effects, was observed with more 
chemotherapy.62–64 However, one has to bear in mind that 
toxicity profiles of the drugs used in these trials were worse 
than the ones related to new third-generation cytotoxic and 
targeted agents. Consequently the use of third-generation 
cytotoxic agents or targeted therapies with a better toxicity 
profile and more convenient administration are attracting 
interest, as they could avoid the development of cancer-
related symptoms by controlling tumor growth without the 
undesirable toxicities associated with the long-term use of 
cytotoxic agents. Moreover, the use of molecularly targeted 
therapies (such as erlotinib) as maintenance raise the possibil-
ity of a more specifically molecular-guided tumor approach 
based on the distinctive biological features of each tumor.
The maintenance approach with targeted therapies was 
initially considered in trials that valued the role of the concur-
rent addition of new targeted agents to chemotherapy as a way 
of seeing whether they could improve outcomes in advanced 
NSCLC patients.16,65–67 In these trials maintenance with the 
targeted agent after induction was allowed until unacceptable 
toxicity or disease progression set in, on the grounds that 
they would delay disease progression with a good tolerability 
profile (Table 1). The TRIBUTE trial,65 a randomized, double-
blind, phase III trial, assigned chemotherapy-naïve advanced 
NSCLC patients with good PS to receive orally erlotinib 
150 mg/daily or a placebo combined with up to 6 cycles 
of carboplatin plus paclitaxel. In the Tarceva Lung Cancer 
Investigation Trial (TALENT)16 patients received 150 mg of 
oral erlotinib daily or a placebo, combined with up to 6 gem-
citabine platinum-based combinations. Both trials failed to 
demonstrate their main objective and provided no evidence of 
a survival advantage with erlotinib added to the cisplatin com-
bination,16,65 or for maintenance with erlotinib. The same holds 
true for the gefitinib trials in first line with chemotherapy.66,67 
However in the TALENT trial, although the proportion of 
patients with objective responses was similar for the erlotinib 
and placebo arm (31.5% vs 29.9%, respectively), the duration 
of the response (though not the median time to symptomatic 
progression) in the experimental arm with erlotinib was small 
but significantly greater (median 25.4 vs 23.9 weeks; HR 0.77; 
P = 0.045).16 The FAST-ACT (First Asian Sequential Tarceva 
and Chemotherapy Trial) is a first-line randomized phase II 
trial of an intermittent erlotinib (days 15 to 28) and gemcit-
abine platinum-based combination (GC) in a majority of the 
Asian population.68 In this trial, responding patients were also 
permitted to continue with erlotinib or placebo until there was 
disease progression or unacceptable toxicity. The trial did not 
achieve its main objective to improve the non-progression 
Table 1 Randomized trials of maintenance therapy with erlotinib
Author Trial design Phase Pts included 
(randomized)
RR (during 
maintenance)
PFS OS QoL 
FACT-L 
Capuzzo75,76 erlotinib vs placebo  
after platinum based  
chemotherapy (SATURN)
iii 1949 (889) 12% vs 5% 
(P = 0.0006)
12.3 vs 11.1 weeks 
(P , 0.0001)
12.3 vs 11.1 months  
(P = 0.0088)
pain and  
analgesic use 
delayed (P ns) 
Miller74 Bevacizumab with  
or without erlotinib  
after platinum-Bevacizumab 
based chemotherapy 
(ATLAS)
iii 1160 (768) NR 4.8 vs 3.7 months 
(P = 0.0012)
NR NR
Mok68 Sequential erlotinib  
vs placebo plus cisplatin- 
gemcitabine (FAST-ACT)
ii 154 NR 29.4 vs 23.4 weeks  
(P = 0.0002)
74.1 vs 75.7 weeks 
(P ns)
NR
Herbst65 erlotinib vs placebo plus 
carboplatin-paclitaxel 
(TRIBUTE)
iii 1059 NR 5.1 vs 4.9 months 
(P ns)
10.6 vs 10.5 months 
(P ns)
NR
Gatzemeier16 erlotinib vs placebo plus  
cisplatin-gemcitabine  
(TALENT)
iii 1172 NR 23.7 vs 24.6 weeks 
(P ns)
43 vs 44.1 weeks 
(P ns)
NR
Abbreviations: Bvz, bevacizumab; QoL, quality of life; OS, overall survival; PFS, progression-free survival; RR, response rate; Pts, patients; ns, non-significant; NR, not-
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rate at 8 weeks with the “pulsed” administration of erlotinib 
(80.3% GC-erlotinib vs 76.9% GC-placebo, P = 0.5143) 
and there were no significant differences in the RR between 
groups (35.5% GC-erlotinib vs 24.4% GC-placebo, P = 0.12). 
However, there was a significant (P = 0.0002) 53% improve-
ment in PFS (29.4 vs 23.4 weeks; HR 0.47) which favors the 
erlotinib plus chemotherapy group.68 Although the majority 
of patients included in the trial were Asian, the observed PFS 
benefit was consistent across all the predefined clinical sub-
groups, including smokers, males and non-adenocarcinoma 
tumor patients.
Other trials with other targeted agents such as   bevacizumab 
or cetuximab,12–14 allowed the continuation of the targeted 
agent after completion of the combination chemotherapy and 
the targeted agent. However these trials were not initially 
designed to evaluate the efficacy of maintenance with the 
targeted agent, and there is no valid control arm for the main-
tenance part of the trials. The data from these trials indicate 
that continuation with the targeted agent is feasible, but they 
do not provide data about the incremental benefit of continuing 
the targeted agent beyond completion of the initial treatment. 
Therefore the question of whether maintenance with cetuximab 
or bevacizumab is helpful in this setting remains unanswered 
until well-designed phase III trials are carried out.
The concept of consolidation, using a non-cross agent 
treatment started before tumor progression, also referred to 
as an “early second-line”, has been investigated in several 
trials.20,69 The prompt use of a different agent to the ones used 
for the induction treatment has some potential   advantages. 
Some authors70–72 suggest that the prompt switch to another 
non-cross resistant agent may reduce the risk of development 
resistant clones that increases over time. Therefore, those 
patients shown to benefit from the upfront treatment with 
a platinum doublet would be candidates for a maintenance 
approach. Consolidation with chemotherapy has recently been 
evaluated; Fidias et al69 could not demonstrate a   statistically 
significant advantage in OS for patients treated immediately 
with docetaxel, started after completion of the first-line treat-
ment with carboplatin and gemcitabine, compared to the 
conventional initiation after disease progression. There were 
no differences in QoL between the two groups and a highly 
significant benefit in terms of PFS (5.7 vs 2.7 months; HR 
0.71) and a trend towards better survival (12.3 vs 9.7 months; 
P = 0.08) was observed for the randomly assigned patients 
in the immediate docetaxel arm as an “early second line”. 
However when patients not receiving docetaxel late second 
line were excluded (n = 98), OS was identical for both groups 
(12.5 months). More recently the JMEN trial,20 a randomized 
phase III trial, has released results showing, for the first time, 
an advantage in terms of OS for a maintenance strategy in 
NSCLC. The trial assigned patients to receive pemetrexed ver-
sus placebo as maintenance after the induction with 4 cycles 
of a platinum combination that did not include   pemetrexed. 
The study achieved its end-point and   demonstrated a highly 
  significant (P , 0.0001) benefit in terms of PFS (4.3 vs 
2.6 months; HR 0.50) and OS (13.4 vs 10.6 months; HR 0.79, 
P = 0.012) with the immediate initiation of pemetrexed.20 
However it is worth mentioning that the trial was not designed 
to test the superiority in OS of pemetrexed over placebo and 
only 18% of patients in the placebo arm ever received pem-
etrexed as systemic post-discontinuation therapy. Interestingly, 
the subset analysis by histology suggested that squamous 
tumors do not benefit from maintenance with pemetrexed in 
terms of PFS and OS.20
The use of targeted agents has also been evaluated in 
consolidation. Unlike cytotoxic agents such as intravenous 
chemotherapy, these targeted treatments may be more appeal-
ing in the maintenance setting and thus are generally well 
tolerated and have a more convenient oral administration for 
patients. Moreover, treatment with targeted therapies may over-
come the undesirable cumulative toxicity caused by cytotoxic 
agents administered in first-line setting. On the other hand, the 
cytostatic rather than cytotoxic properties of the new targeted 
drugs makes them a potential candidate for use in patients who 
have already shown a response after the initial chemotherapy 
by maintaining the tumor responses and delaying the progres-
sion event. In 2009, the results of 2 major phase III studies, 
ATLAS and SATURN, which evaluated the role of the TKI 
erlotinib as single-agent maintenance therapy in advanced 
NSCLC either with of without bevacizumab, an anti-VEGF 
receptor, were released in the annual American Society of 
Clinical Oncology meeting.73,74 These trials offered the pos-
sibility of continuing an active treatment with erlotinib after 
completing chemotherapy in order to delay disease   progression 
and symptom deterioration. SATURN (Sequential Tarceva in 
Unresectable NSCLC)73 is a   randomized, placebo-controlled 
phase III trial in which erlotinib was evaluated as first-line 
  maintenance therapy in advanced NSCLC patients whose 
disease had not progressed after 4 cycles of a platinum-doublet 
treatment. In this trial patients received erlotinib (150 mg/
day) or placebo until disease progression or unacceptable 
toxicity, if disease   control (stable disease, partial response or 
complete response) was documented after the 4 initial cycles 
of chemotherapy (Figure 5). Tissue samples of the randomized 
patients were   collected at baseline. The primary end-points 
were to   determine whether the administration of erlotinib, as Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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maintenance after the standard platinum-based chemotherapy, 
increases PFS in all patients and in those whose tumors express 
EGFR by inmunohistochemistry (IHQ). Secondary end-points 
included determining OS throughout the population and in 
patients according to protein expression of EGFR, as well as 
the analysis of other different biomarkers (EGFR gene copy 
number by fluorescent in situ hybridization – FISH, EGFR 
and Kras mutations with intron 1 CA-repeat polymorphism at 
EGFR by sequencing). Among the 889 patients randomized, 
out of a total of 1949, PFS (assessed by an investigator and 
an independent review and defined as the length of time from 
randomization to disease progression or death from any cause) 
was significantly prolonged with erlotinib versus placebo (HR 
0.71; 95% CI 0.62 to 0.82; P , 0.0001). There was a 41% 
improvement in PFS but the absolute differences were less than 
we might have hoped (12.3 vs 11.1 weeks). The percentage of 
patients without progression at 3 and 6 months were 53% vs 
40% and 31% vs 17% for the erlotinib and the placebo group 
respectively. In patients whose tumors expressed EGFR by 
IHQ (n = 618), the absolute benefit for erlotinib was 45% (HR 
0.69; 95% CI 0.58 to 0.82; P , 0.0001). Although the advan-
tage in PFS was observed for all the subgroups of population 
analyzed (HR 0.71), mean PFS was significantly increased by 
1 month (3.75 vs 4.76 months; HR 0.72) in women, people 
with Asian ethnicity and never-smokers. It is worth mention-
ing that although the patients included in the trial had already 
responded to the induction chemotherapy, maintenance with 
erlotinib achieved an overall RR of 12% vs 5% in the placebo 
group (P = 0.0006) and the disease control rate after 12 weeks 
of treatment, in the erlotinib group, was almost double that of 
the placebo arm (40.8% vs 27.4%, P = 0.0001). In general, 
erlotinib was well tolerated; the withdrawals from the study due 
to treatment-related adverse events were mild without differ-
ences in both groups and the major treatment-related toxicities 
were the anticipated grade I/II rash and diarrhea. Nevertheless, 
the assessment of QoL by the FACT-L (  Functional Assessment 
of Cancer Therapy-Lung questionnaire) provided no evidence 
of a significant benefit, or impairment, in QoL with the active 
treatment (HR 0.96, 95% CI 0.79 to 1.16; P = 0.6530), and only 
pain and analgesic use seemed to be significantly delayed with 
the erlotinib manteinance.73
Later in the year, the much anticipated final results on 
survival were released at the 13th World Conference of 
Lung Cancer and the 34th ESMO congress.75,76 Maintenance 
with erlotinib significantly increased OS vs placebo in the 
intention-to-treat advanced NSCLC patients (HR 0.81, 
95% CI 0.70 to 0.95; P = 0.0088), but as observed for PFS, 
the absolute differences in OS with erlotinib were minor (12.3 
vs 11.1 months). However, OS differences for non-squamous 
disease treated with erlotinib appeared more worthwhile 
(13.7 vs 10.5 months, HR 0.79; P = 0.01). Among subgroup 
analysis, the greatest advantage in OS was observed for 
aCarbo/paclitaxel; cis/vinorelbine; carbo or cis/gemcitabine; carbo or cis/docetaxel.
Figure 5 Design of erlotinib maintenance phase III trials in advanced NSCLC treatment (SATURN73 and ATLAS74).
Abbreviations: NSCLC, non-small cell lung cancer; non-PD, complete responses, partial responses, stable disease; PD, progressive disease; PFS, progression-free survival.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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women (HR 0.64), people with Asian ethnicity (HR 0.66), 
never-smokers (HR 0.69) and adenocarcinoma tumors 
(HR 0.77), although all the subgroups of population analyzed 
gain a survival benefit from erlotinib maintenance. Interest-
ingly, the magnitude of the benefit was greater in patients 
with stable disease following first-line chemotherapy than 
in those achieving a complete or partial response. Erlotinib, 
compared with placebo, gave patients with stable disease 
a 39% improvement in OS and a 2.3-month improvement 
in median survival (11.9 months vs 9.6 months; HR 0.72; 
P = 0.0019). Based on these results the European Commis-
sion (EMEA) has approved erlotinib as monotherapy for 
maintenance treatment in patients with locally advanced or 
metastatic NSCLC with stable disease following 4 cycles of 
standard platinum-based first-line chemotherapy.
The initial planned biomarker assessment revealed that 
the benefit on PFS was observed in all patients subgroups 
  regardless EGFR or Kras mutation status.77 Some groups 
  benefited disproportionally from erlotinib such as EGFR posi-
tive by IHQ (HR 0.69) or by FISH (HR 0.68) and wild type 
Kras (HR 0.70). On the other hand, the strongest   benefit in 
PFS was observed for the 49 patients with mutation at EGFR 
exon 19 or 21 (HR = 0.10; 95% CI 0.04 to 0.25; P , 0.0001), 
whereas EGFR wild type tumors seemed to benefit more 
from the erlotinib treatment (HR 0.77) compared to EGFR 
mutated tumors (HR 0.83).77 These confusing results might 
be explained by the high level (67%) of subsequent EGFR 
tyrosine kinase inhibitor use in the placebo arm after progres-
sion in the EGFR mutated group, by the immature data on 
OS or by the unrepresentatively small sample in the subset 
analysis (n = 49). Meanwhile, multivariate analyses are needed 
for biomarker analysis as many of these   biomarker-selected 
groups may overlap.
The randomized, double-blind, placebo-controlled, phase 
IIIB ATLAS (Adjuvant Tamoxifen Longer Against Shorter) 
trial, comparing bevacizumab therapy with or without erlo-
tinib, after completion of chemotherapy with bevacizumab 
for the treatment of locally advanced, recurrent, or metastatic 
NSCLC, is the second important trial designed to assess the 
role of maintenance with bevacizumab with or without erlo-
tinib74 (Figure 5). Patients were initially treated with 4 cycles 
of bevacizumab in combination with the investigators’ choice 
of platinum-based chemotherapy regimens. If their cancer did 
not progress and they did not experience significant toxicity, 
patients were then randomized (n = 768) to receive mainte-
nance therapy with bevacizumab (15 mg/kg) plus erlotinib 
(150 mg/day) or placebo until disease progression. Patients 
with treated brain metastases, those receiving anticoagulation 
treatment with low-molecular-weight heparin and peripheral 
squamous tumors were also eligible for the study. The 
primary objective of the study was PFS started from the 
beginning of the maintenance phase after initial treatment 
with chemotherapy and bevacizumab, and the secondary 
included safety assessment and OS. The ATLAS study was 
prematurely stopped on the recommendation of an indepen-
dent data safety monitoring board after a pre-planned interim 
efficacy analysis showed the study met the primary end-point 
and that combining erlotinib and bevacizumab significantly 
extended the time patients live without disease progression 
compared to bevacizumab plus placebo.78 The preliminary 
safety analysis also gave evidence of a safe toxicity profile 
with adverse events consistent with other previous studies of 
bevacizumab and erlotinib and no new safety signals were 
observed. The median PFS was 4.8 months for bevacizumab 
and erlotinib vs 3.7 months for bevacizumab without erlotinib 
(HR 0.72, 95% CI 0.59 to 0.88; P = 0.0012). The   percentage 
of patients without progression at 3 months was 67% for 
the erlotinib group vs 53% for the placebo group and at 
6 months was 40% and 28% respectively.74 The results on 
OS are expected for the first half of 2010. The trial included 
a prospective analysis of several biomarkers,79 EGFR IHQ, 
gene copy number by FISH and EGFR and Kras mutations 
by sequencing. The results suggest that EGFR FISH positive 
(HR 0.66), EGFR mutated (HR 0.44) and Kras wild type 
(HR 0.67) patients, could derive the greatest improvement 
in PFS with bevacizumab and erlotinib.79
Resistance to erlotinib in EGFR 
mutant patients and future 
therapeutic strategies
In NSCLC patients carrying EGFR mutations the treatment 
with first generation TKIs provides dramatic clinical and 
radiological responses; overall, EGFR mutations carriers 
have a RR around 75%, compared with a RR lower than 10% 
for patients with wild type EGFR.80 Furthermore, patients 
with EGFR mutations have been shown to have longer 
  progression-free and OS.46 Despite this encouraging data, 
almost all cases invariably develop “acquired” resistance 
to TKIs,40 which means the progression of the tumor that 
had   previously responded to the treatment. About 43% to 
50% of cases with acquired resistance to reversible EGFR 
TKIs can be accounted for by a secondary mutation, the 
gatekeeper mutation T790M located in exon 20 of the EGFR 
kinase domain.81 This acquired alteration increases the ATP 
binding affinity of EGFR approximately 10-fold in the pres-
ence or absence of a TKI allowing ATP to competitively Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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displace gefitinib and erlotinib from EGFR.82 At least 10 
other activating mutations (less common single amino acid 
substitutions such as D761Y, L747S, and T854A) have been 
reported within the kinase domain and the novel E884K 
mutation has been associated with resistance to gefitinib 
and erlotinib.83
Balak et al noted that given the proportion of patients with 
acquired resistance, whose tumors contain T790M, malignant 
cells remain dependent on mutant EGFR for survival in at least 
half of patients.84 On the other hand, the T790M mutation can 
also be detected in pretreatment specimens (38%), a condi-
tion that was associated with a short PFS (7.7 months vs 16.5 
months in those without the mutation; HR for progression for 
the T790M allele, 11.5; P , 0.001).85 All these aspects provide 
a rationale for developing second generation of irreversible 
TKIs, such as HKI-272, EKB-569, CI-1033 and BIBW2992, 
that bind covalently with the catalytic pocket of the TK recep-
tor providing a sustained blockade against tumors harboring 
the T790 mutation.86 Currently some phase II clinical trials 
with second-line TKIs, suggest a RR as high as 50% in some 
small cohorts, although only stable disease at best has been 
documented in patients with known T790M mutations.87–89
Another 20% of cases of acquired TKI resistance involve 
amplification of the MET proto-oncogen.90 In this resistant 
tumors, amplification of MET activates PI3K-AKT signaling 
through erbB3.90 IGFR-1R is another potential mechanism of 
escape to the therapeutic effect of TK reversible inhibitors.91 
Heterodimerization of the EGFR/IGFR-1R stimulates down-
stream pathways such as PI3K/AKT and MAPK, resulting in 
mammalian target of rapamycin (mTOR)-mediated protein 
synthesis of EGFR in NSCLC cells.92,93 These preclinical 
studies support the rational for clinical trials designs with 
combined treatment of a reversible TKI along with MET 
kinase, IGFR-1R or mTOR inhibitors. This approach could 
further improve the current results obtained with a single-
agent in a subgroup of NSCLC patients with EGFR mutations 
and acquired resistance.94
As reversible EGFR TKIs are now established as standard 
first-line therapy for patients with lung cancer with EGFR 
mutation, thoracic oncologists expect to see more patients 
with acquired resistance.50 To simplify the definition of 
acquired resistance, recently Jackman et al proposed 4 easy 
and largely clinical criteria relevant to clinicians in their regu-
lar practice and to researchers in their design of studies.95 The 
first criterion relates to patients who had previously received 
treatment with single-agent EGFR TKI; the second, that the 
tumor meet one or other of the following items: (A) that it 
harbors an EGFR mutation known to be associated with drug 
sensitivity; or (B) the patients do present clinical benefit from 
treatment with EGFR TKI (ie, either documented partial or 
complete response (RECIST or WHO), or a significant and 
durable (.6 months) stable disease after initiation TKIs); 
thirdly, there must be some evidence of systemic progression 
of disease while on continuous treatment with gefitinib or 
erlotinib within the last 30 days; and finally, that there is no 
intervening systemic therapy between cessation of the TKI 
and initiation of new therapy.95 However, there is a small 
subgroup of EGFR mutant patients with primary, poorly 
understood resistance (6.5% to 10%) who never respond to 
first-line TKI therapy.96
Conclusions
As highlighted by this review, erlotinib is an oral TKI 
with demonstrated activity in NSCLC. Thus far, erlotinib 
  indications in NSCLC include all subgroups of locally 
advanced or metastatic NSCLC after failure of at least 
one prior chemotherapy regimen. In this context, erlotinib 
  treatment improves OS and patient QoL. Erlotinib was 
clinically developed in parallel with the recent recogni-
tion of EGFR as a marker of response to TKIs. There is 
no doubt that NSCLC patients harboring EGFR mutations 
have a   biologically different entity that requires personalized 
treatment strategies, including the use of TKIs instead of 
the   unselective chemotherapy. Therefore, erlotinib clinical 
research has moved from second to first line, and at present, 
ongoing phase III trials aim to find out if erlotinib can be 
considered a new standard option in first-line intervention 
for patients harboring EGFR mutations. On the other hand, 
maintenance approach has recently received great attention as 
a suitable option in advanced NSCLC. Based on the results of 
the pivotal SATURN phase III trial, erlotinib as monotherapy 
has just been approved for patients with advanced NSCLC 
with non-progressive (FDA) or stable disease (EMEA), after 
first-line platinum-based initial chemotherapy. However, there 
still has been little movement toward accepting maintenance 
chemotherapy after first-line treatment, and many detractors 
cite the negligible survival benefit as the key reason. More 
convincing evidence for this approach could come from a 
prospective trial comparing the maintenance strategy with the 
same drug administered soon after first-line chemotherapy 
completion or after a demonstrated disease progression as a 
second line. Nevertheless, the concept of giving patients an 
oral, generally well-tolerated therapy such as erlotinib may be 
more appealing in the maintenance setting than more standard 
IV chemotherapy. To date, the SATURN trial, designed to 
test the role of erlotinib as maintenance treatment after initial Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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chemotherapy, is the only randomized trial to demonstrate 
a significant survival advantage of maintenance with the 
use of a targeted agent. Unfortunately, most of the absolute 
advantages reported represent a restricted progress in the 
treatment of advanced NSCLC. Efforts have to be focused 
on identifying molecular predictive markers for a selective, 
rather than indiscriminate, treatment in NSCLC.
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